𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer

✍ Scribed by Bent Ejlertsen; Henning T. Mouridsen; Maj-Britt Jensen; Jørn Andersen; Michael Andersson; Claus Kamby; Ann S. Knoop; for the Danish Breast Cancer Cooperative Group

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
309 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant six cycles of high-dose adriamy
Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose acmf with tamoxifen for premenopausal, node-positive breast cancer patients: Results of a prospective randomized study
✍ Dr. Takashi Fukutomi; Sadako Akashi; Takeshi Nanasawa; Hiroshi Yamamoto 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB

A prospective randomized study was conducted to compare the adjuvant efficacy of six cycles of high-dose ACMF (Adriamycin, ADM; cyclophosphamide, CPA; methotrexate, MTX; 5-fluorouracil, 5-FU) with that of 12 cycles of low-dose ACMF in premenopausal, node-positive breast cancer patients. The six-cycl

Phase 2 trial of primary systemic therap
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099
✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views